Journal article
Abstract CT212: A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36
Abstract
Abstract
Introduction: Analyses of circulating tumor DNA (ctDNA) have shown promise in capturing tumor burden dynamics during immune checkpoint blockade (ICB), with the potential to allow patients with primary resistance to be rapidly identified and redirected to alternative therapies.
Authors
Anagnostou VK; Ho C; Nicholas G; Juergens RA; Sacher A; Fung A; Wheatley-Price P; Laurie S; Levy B; Brahmer J
Journal
Cancer Research, Vol. 83, No. 8_Supplement, pp. ct212–ct212
Publisher
American Association for Cancer Research (AACR)
Publication Date
April 14, 2023
DOI
10.1158/1538-7445.am2023-ct212
ISSN
0008-5472